CENTRAL TRUST Co Buys 23,044 Shares of Pfizer Inc. $PFE

CENTRAL TRUST Co raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 454,538 shares of the biopharmaceutical company’s stock after purchasing an additional 23,044 shares during the quarter. CENTRAL TRUST Co’s holdings in Pfizer were worth $11,018,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Westbourne Investments Inc. bought a new position in Pfizer in the first quarter valued at approximately $2,411,000. Bourne Lent Asset Management Inc. lifted its stake in shares of Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares during the period. Strs Ohio bought a new position in shares of Pfizer in the 1st quarter worth $49,968,000. IFM Investors Pty Ltd grew its stake in shares of Pfizer by 3.8% during the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock worth $27,322,000 after purchasing an additional 41,263 shares during the period. Finally, Intrua Financial LLC increased its holdings in Pfizer by 17.4% in the first quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock valued at $1,986,000 after purchasing an additional 11,643 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.1%

Shares of Pfizer stock opened at $24.40 on Tuesday. The firm has a market cap of $138.73 billion, a PE ratio of 12.98, a P/E/G ratio of 0.81 and a beta of 0.54. The business’s 50 day simple moving average is $24.74 and its 200 day simple moving average is $24.39. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $28.18.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.